share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股SEC公告 ·  07/11 16:19

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals Inc. has announced an amendment to its Form 8-K filing, initially submitted on July 1, 2024, regarding its 2024 annual meeting of stockholders and related deadlines for stockholder proposals. The amendment, filed on July 11, 2024, clarifies the record date for the annual meeting, which is now set for August 12, 2024. The company's Board of Directors has scheduled the 2024 Annual Meeting for October 2, 2024. Due to the absence of an annual meeting in 2023, Conduit Pharmaceuticals is informing shareholders of the July 11, 2024 deadline for the submission of qualified stockholder proposals or director nominations to be included in the proxy statement. All proposals must adhere to the SEC's rules and regulations, including Rule 14a-8 under the Exchange Act, as well as the company's bylaws.
Conduit Pharmaceuticals Inc. has announced an amendment to its Form 8-K filing, initially submitted on July 1, 2024, regarding its 2024 annual meeting of stockholders and related deadlines for stockholder proposals. The amendment, filed on July 11, 2024, clarifies the record date for the annual meeting, which is now set for August 12, 2024. The company's Board of Directors has scheduled the 2024 Annual Meeting for October 2, 2024. Due to the absence of an annual meeting in 2023, Conduit Pharmaceuticals is informing shareholders of the July 11, 2024 deadline for the submission of qualified stockholder proposals or director nominations to be included in the proxy statement. All proposals must adhere to the SEC's rules and regulations, including Rule 14a-8 under the Exchange Act, as well as the company's bylaws.
Conduit Pharmaceuticals Inc.宣布对其2024年股东大会及相关提案截止日期的8-K表格文件进行修正,该文件最初于2024年7月1日提交。修正版于2024年7月11日提交,澄清了年度股东会的记录日期,目前已设定为2024年8月12日。公司董事会已将2024年董事会议定于2024年10月2日举行。由于2023年没有举行年度会议,Conduit Pharmaceuticals正在告知股东关于提交符合要求的股东提案或董事提名以包括在委托书中的截止日期为2024年7月11日。所有提案必须遵守SEC的规则和法规,包括《交易所法案》第14a-8条,以及公司的章程。
Conduit Pharmaceuticals Inc.宣布对其2024年股东大会及相关提案截止日期的8-K表格文件进行修正,该文件最初于2024年7月1日提交。修正版于2024年7月11日提交,澄清了年度股东会的记录日期,目前已设定为2024年8月12日。公司董事会已将2024年董事会议定于2024年10月2日举行。由于2023年没有举行年度会议,Conduit Pharmaceuticals正在告知股东关于提交符合要求的股东提案或董事提名以包括在委托书中的截止日期为2024年7月11日。所有提案必须遵守SEC的规则和法规,包括《交易所法案》第14a-8条,以及公司的章程。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息